Drugs / EN3348
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01200992 | Nov 2010 → Apr 2013 | in situ carcinoma, mycobacterial infectious disease, transitional cell carcinoma, urinary bladder neoplasm | Bioniche Life Sciences Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EN3348 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01200992 ↗ |
| Known as | MCC | “Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment” NCT01200992 ↗ |